Early company creation can rely on small bets across many projects searching for a rare outlier like Moderna. In Series A and B rounds, ticket sizes are too large for spray-and-pray tactics, forcing investors to fund companies toward clear milestones within 18 to 24 months.
While multi-billion-euro funds are vital for later-stage European life sciences, their dominance absorbs available institutional capital and strains smaller fund raising. Sustaining a healthy innovation ecosystem requires democratizing institutional allocations rather than directing all capital to mega-funds.
Investors with clinical development heritage struggle to underwrite pure platforms without visible therapeutic applications. Even prominent platform successes ultimately depended on substantial capital deployment into specific lead pipeline assets to reach major commercial inflection points.
High-performing venture funds execute strict portfolio triage, refusing follow-on funding to underperforming companies regardless of past participation. Evenly distributing capital across all portfolio assets starves top-tier winners of the resources required to achieve critical clinical milestones.
Integrating institutional co-investors like the European Investment Bank imposes formal governance on corporate venture entities. Serving public and private partners enforces strict information boundaries, preventing corporate contamination while granting early-stage biotechs protection against unfair corporate terms.
Because life science venture capital suffers from severe information asymmetry, financial models alone cannot de-risk deals. Junior investors must build enduring relationships with peers across academia and industry to access authentic, specialized domain expertise when evaluating complex scientific data.
